Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis

Table 1 Distribution of the factors used in the propensity score matching in the general population (n = 50), n (%)

	Resection, n = 25	TACE, n = 25	Total, n = 50	P value
AFP, n (%)				0.243
< 400 ng/mL	20 (90.9)	17 (73.9)	37 (82.2)
> 400 ng/mL	2 (9.1)	6 (26.1)	8 (17.8)
Missing	3	2	5
Cirrhosis, n (%)				0.002
No	9 (36)	0	9 (18)
Yes	16 (64)	25 (100)	41 (82)
Child-Pugh score, n (%)				0.840
A5	12 (48)	10 (40)	22 (44)
A6	9 (36)	11 (44)	20 (40)
B7	4 (16)	4 (16)	8 (16)
MELD	8.4 ± 2.7	9.7 ± 2.2	9 ± 2.5	0.069
Number of lesions	2 (2-10)	4 (2-7)	2.5 (2-10)	0.008
Tumor diameter (mm)	69.5 ± 52.2	41.9 ± 17	55.7 ± 40.9	0.018

TACE: Trans-Arterial ChemoEmbolization; AFP: Alpha-fetoprotein; MELD: Model for End-Stage Liver Disease.